ClinicalTrials.gg
CompletedNCT00656084Updated Nov 3, 2016Results posted

Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell

A Phase 2 interventional study of gemcitabine and mitoxantrone in Relapsed or Refractory Mantle Cell Lymphoma (MCL), sponsored by US Oncology Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.

Primary conditionLymphoma, Mantle-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Mantle-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gemcitabine in Lymphoma, Mantle-Cell — none open to participants now, none under way, none of them phase 3. Gemcitabine · Lymphoma, Mantle-Cell.

Enrollment
9th of 10
16 · median 30
Started
2004
the only one that year
Phase 2
6 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
US Oncology Research

Among the 11 studies testing gemcitabine in Lymphoma, Mantle-Cell, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2004, is one of 6 in phase 2, and was the 9th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

None of the 11 studies testing gemcitabine in Lymphoma, Mantle-Cell is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing gemcitabine in Lymphoma, Mantle-Cell as a file.
02

Study summary

To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL

03

Conditions studied

  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Browse trials for

04

In context

Lymphoma, Mantle-Cell Reclassified

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

This study's enrollment of 16 is below the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.

First submitted before US Oncology Research became part of Sarah Cannon Research Institute.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage III or IV, confirmed MCL as reviewed by the SI
  • Is CD20 positive (by immunohistochemistry or FACS)
  • Is Cyclin D positive (by immunohistochemistry or FACS)
  • Has received prior chemotherapy (required minimum of 1 prior therapies)
  • Has received prior treatment with Rituxan
  • Has an Performance Status (PS) 0-2
  • Is greater than or equal to 18 years of age
  • Has appropriate laboratory values (please refer to protocol for specific laboratory values)
  • If a history of cardiac disease is indicated, patient has an greater than or equal to 50% (MUGA)
  • Has a negative serum pregnancy test within 7 days prior to registration (female patients of )
  • If fertile, patient (male or female) has agreed to use an acceptable method of to avoid pregnancy for the duration of the study and for a period of 2 months thereafter
  • Has signed a Patient Form
  • Has signed a Patient Authorization Form

Exclusion criteria

Exclusion Criteria:

  • Has other lymphomas not classified as MCL
  • Has had prior treatment with Gemzar and/or Novantrone
  • A history of known to Gemzar, Novantrone, Rituxan, or any component of these drugs
  • Has a history of hypersensitivity to murine-cell derived therapeutics
  • Has a indicative of a cardiac condition (LVEF \< 50%)
  • Is receiving concurrent immunotherapy
  • Has evidence of CNS involvement
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  • Has a history of other within the last 5 years (except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs
  • Is a pregnant or nursing woman
  • Is unable to comply with requirements of study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Experimental arm

    Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.

    Drug: gemcitabine · Drug: mitoxantrone · Drug: rituximab

Interventions

  • 900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.

    Also known as: Gemzar

  • Novantrone 10 mg/m2on Day 1. The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.

    Also known as: Novantrone

  • Rituxan 375 mg/m2 on Day 1. The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.

    Also known as: Rituxan

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (CR + PR)

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: 2 years

Secondary outcomes

  1. Duration of Response

    The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 33 months.

  2. Overall Survival (OS) Rate at 1 Year

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 1 year.

  3. Progression-free Survival Rate at 1 Year.

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.

    Time frame: 1 year.

08

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneGemzar + Novantrone + Rituxan
Started16
Completed9
Not completed7
Withdrew: Adverse event4
Withdrew: Withdrawal by subject1
Withdrew: Patient request1
Withdrew: Investigator request1

Outcome measures

PrimaryObjective Response Rate (CR + PR)

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
2 years
Reported as:
Number · percentage of participants
Objective Response Rate (CR + PR)
percentage of participantsGemzar + Novantrone + Rituxan
Objective Response Rate (CR + PR)46.7 (21.3 to 73.4)
SecondaryDuration of Response

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 33 months.
Reported as:
Median · months
Duration of Response
monthsGemzar + Novantrone + Rituxan
Duration of Response7.9 (4.8 to 31.3)
SecondaryOverall Survival (OS) Rate at 1 Year

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
1 year.
Reported as:
Number · Probability of Survival
Overall Survival (OS) Rate at 1 Year
Probability of SurvivalGemzar + Novantrone + Rituxan
Overall Survival (OS) Rate at 1 Year0.57 (0.28 to 0.78)
SecondaryProgression-free Survival Rate at 1 Year.

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.

Time frame:
1 year.
Reported as:
Number · Probability of Progression-free Survival
Progression-free Survival Rate at 1 Year.
Probability of Progression-free SurvivalGemzar + Novantrone + Rituxan
Progression-free Survival Rate at 1 Year.0.54 (0.24 to 0.77)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemzar + Novantrone + Rituxan—4/15 (26.7%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventGemzar + Novantrone + Rituxan
FEVERGeneral disorders2/15
CACHEXIAGeneral disorders1/15
PAIN ABDOGastrointestinal disorders1/15
Most frequent other events
Showing 10 of 62
Most frequent other events
EventGemzar + Novantrone + Rituxan
NEUTROPENIABlood and lymphatic system disorders15/15
ASTHENIAGeneral disorders14/15
ANEMIABlood and lymphatic system disorders13/15
THROMBOCYTOPENIABlood and lymphatic system disorders12/15
LEUKOPENIABlood and lymphatic system disorders9/15
NAUSEAGastrointestinal disorders9/15
ANOREXIAGastrointestinal disorders7/15
CONSTIPGastrointestinal disorders6/15
ALOPECIASkin and subcutaneous tissue disorders3/15
DIZZINESSNervous system disorders3/15

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Gemzar + Novantrone + Rituxan
Mean68 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Gemzar + Novantrone + Rituxan
Female5
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Gemzar + Novantrone + Rituxan
Caucasian16
Region of Enrollment
Region of Enrollment(participants)Gemzar + Novantrone + Rituxan
United States16
09

Study locations

No study locations are listed for this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jan 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 9 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2008
First posted
Apr 10, 2008
Start
Dec 2004
Primary completionActual
Jan 2007
CompletionActual
Jan 2008
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00656084
First posted
Apr 10, 2008
Start date
Dec 2004
Primary completion
Jan 2007
Completion
Jan 2008
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Lawrence Garbo, MD
principal investigator · US Oncology Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Mitoxantrone · Rituximab

Start the discussion